title: Tolerance to enteral tube feeding diets in hypoalbuminemic critically ill, geriatric patients.
abstract: Tolerance of elemental (for example, Peptamen [PEP]) or free amino acid (for example, Vivonex TEN [VIV]) tube feeding diets is controversial, especially in the critically ill patient who is hypoalbuminemic. A prospective, randomized trial was conducted to compare differences between feeding PEP (n = 8) or VIV (n = 8) in critically ill, elderly (average age of 66 years) patients. Diets were administered through nasogastric or postpyloric feeding tubes. Eleven patients had diseases of the gastrointestinal tract; all underwent surgical treatment. Patients were fed each diet at full strength, beginning with 20 to 30 milliliters per hour and advancing by 10 to 20 milliliters every day until goal rate was reached, usually on day 4. Assessment was made for ability to comply with rate of tube feeding ordered, compliance with caloric goal and tolerance (as evidenced by abdominal discomfort and diarrhea). Diarrhea was qualitatively defined as more than three stools per day and then quantitatively as the mean number of stools daily. There were no significant differences between the two groups in terms of compliance with prescribed tube feeding order or caloric goal or the presence of diarrhea and abdominal discomfort. There was a significant difference between the two groups in terms of the actual number of stools per day (PEP equals 1.38 versus VIV equals 2.25, p less than 0.02). Serum albumin concentrations upon initiation of the diets were 2.3 grams per deciliter in both groups. We conclude that tolerance to the two diets were similar because it was possible to feed enterally either PEP or VIV in critically ill, hypoalbuminemic patients (serum albumin concentrations of less than 2.5 grams per deciliter) successfully, irrespective of diet. Although there were more stools in the VIV group, this did not reduce compliance with the goals.
authors.affiliation: Department of Surgery, Harvard Medical School, Deaconess Hospital, Boston, Massachusetts 02215.
authors.forename: B C
authors.initials: BC
authors.lastname: Borlase
authors.forename: S J
authors.initials: SJ
authors.lastname: Bell
authors.forename: E J
authors.initials: EJ
authors.lastname: Lewis
authors.forename: W
authors.initials: W
authors.lastname: Swails
authors.forename: B R
authors.initials: BR
authors.lastname: Bistrian
authors.forename: R A
authors.initials: RA
authors.lastname: Forse
authors.forename: G L
authors.initials: GL
authors.lastname: Blackburn
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016638:Critical Illness; D002149:Energy Intake; D004750:Enteral Nutrition / Q000009:adverse effects; D005260:Female; D005503:Food Additives / Q000008:administration & dosage / Q000009:adverse effects; D005526:Food, Formulated / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009748:Nutrition Disorders / Q000097:blood / Q000628:therapy; D009842:Oligopeptides; D009930:Organic Chemicals; D010349:Patient Compliance; D011446:Prospective Studies; D012709:Serum Albumin / Q000032:analysis*
chemical_list: D005503:Food Additives; D009842:Oligopeptides; D009930:Organic Chemicals; C073248:Peptamen; D012709:Serum Albumin; C011567:Vivonex